Juan Carlos JARAMILLO

About Juan Carlos JARAMILLO

Juan Carlos Jaramillo, MD, holds a senior executive position at Valneva SE, where he serves as Chief Medical Officer and, following the board appointment on December 20, 2023, as an Associate Managing Director / Directeur général délégué. He joined Valneva in October 2020 as a member of the Management Board, bringing substantial international experience in medical affairs, clinical development, and market access. In a specialty vaccine company such as Valneva, his role is central to aligning scientific strategy, development priorities, and commercial readiness. Before joining Valneva, Jaramillo built a broad career in global pharmaceuticals. Valneva states that he held senior positions at Daiichi Sankyo, Grünenthal, and GlaxoSmithKline. His background spans vaccines and therapeutics, as well as global market access and pricing strategy, giving him a profile that combines medical leadership with a strong business perspective. The company also highlights his deep understanding of healthcare systems across multiple geographies, which is an important asset in international biopharma decision-making. His appointment at Valneva in 2020 came at a time when the company was advancing a number of major vaccine programs. At the time, Valneva emphasized his strong track record across a wide range of settings, therapeutic areas, and regions, as well as his multicultural leadership style. Since then, his progression to an expanded executive role reflects the company’s confidence in his leadership and his contribution to the group’s strategic development. Jaramillo’s core expertise lies at the intersection of science, strategy, and execution. He brings together clinical and medical leadership, access and pricing knowledge, and experience navigating complex regulatory and healthcare environments. For a listed vaccine company, that combination is especially valuable: it supports disciplined clinical programs, informed stakeholder engagement, and a stronger bridge between R&D and commercialization. His career therefore positions him as a key executive in Valneva’s governance and long-term growth framework.